Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2020-11-20. The firm specializes in complex injectables and is engaged in the sterile injectables, oncology, and ophthalmology segments. The firm provides contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a variety of delivery systems. Its products are available in liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Blood Related, Cardiac, Gastrointestinal, Gynaecological, Hormones, Neuro / Cns, Ophthal / Otologicals, Pain/Analgesics, Respiratory and Vitamins / Minerals / Nutrients. Its products are sold across various countries, which include United States, Europe, Canada, and others.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.